Handelsbanken Fonder
NKTR icon

Handelsbanken Fonder’s Nektar Therapeutics NKTR Stock Holding History

Handelsbanken Fonder’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-929
Closed -$10K – 1610
2023
Q1 		$10K Hold
929
– – ﹤0.01% 1563
2022
Q4 		$31K Hold
929
– – ﹤0.01% 1554
2022
Q3 		$45K Hold
929
– – ﹤0.01% 1560
2022
Q2 		$53K Sell
929
-1,373
-60% -$86.6K ﹤0.01% 1605
2022
Q1 		$186K Hold
2,302
– – ﹤0.01% 1643
2021
Q4 		$467K Hold
2,302
– – ﹤0.01% 1398
2021
Q3 		$620K Hold
2,302
– – ﹤0.01% 1209
2021
Q2 		$593K Hold
2,302
– – ﹤0.01% 1253
2021
Q1 		$691K Hold
2,302
– – ﹤0.01% 1022
2020
Q4 		$587K Hold
2,302
– – ﹤0.01% 1076
2020
Q3 		$573K Hold
2,302
– – ﹤0.01% 934
2020
Q2 		$800K Buy
+2,302
New +$718K 0.01% 773
2019
Q3 		– Sell
-3,936
Closed -$2.1M – 189
2019
Q2 		$2.1M Sell
3,936
-1,080
-22% -$542K 0.04% 171
2019
Q1 		$2.53M Buy
5,016
+747
+17% +$443K 0.05% 165
2018
Q4 		$2.1M Buy
4,269
+902
+27% +$544K 0.04% 157
2018
Q3 		$3.08M Buy
3,367
+1,334
+66% +$1.14M 0.06% 159
2018
Q2 		$1.49M Sell
2,033
-1,167
-36% -$1.35M 0.03% 176
2018
Q1 		$5.1M Sell
3,200
-1,400
-30% -$1.8M 0.1% 147
2017
Q4 		$4.12M Buy
+4,600
New +$2.72M 0.09% 143

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Handelsbanken Fonder's NKTR Position: Q2 2023 in Review

Handelsbanken Fonder sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 929 shares — an estimated $10K sold.

Handelsbanken Fonder first reported a position in NKTR in Q4 2017 and held it in 19 quarters. The position peaked at $5.1M in Q1 2018. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

  • Handelsbanken Fonder reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Handelsbanken Fonder sold 929 Nektar Therapeutics shares in Q2 2023, an estimated $10K.
  • Handelsbanken Fonder first reported a position in Nektar Therapeutics in Q4 2017 and held it in 19 quarters.
  • Handelsbanken Fonder's Nektar Therapeutics position peaked at $5.1M in Q1 2018.
  • 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Handelsbanken Fonder's 13F filing for Q2 2023, filed 2 Aug 2023.